Work

Long-term outcomes of avelumab maintenance in older patients with advanced urothelial carcinoma in Japan from the JAVEMACS study

Year: 2026
Type: article
Abstract: The retrospective JAVEMACS chart review study described outcomes of avelumab first-line maintenance for patients with locally advanced/metastatic urothelial carcinoma without progression after platinum-based chemotherapy (PBC) in Japanese real-world practice. This post hoc exploratory analysis compared outcomes by age at avelumab initiation (<​75 vs. ≥​75 [main] and <​80 vs. ≥​80 years [supportive]). Stabilized inverse probability of treatment weighting estimated covariate-standardized associations; causal inference was not intended. Overall survival (OS) and progression-free survival (PFS) were assessed using unadjusted and weighted Kaplan-Meier and Cox models. Among 349 patients, 206 (59.0%) and 143 (41.0%) were <​75 and ≥​75 years, respectively. In the complete-case propensity score analysis set (n = 267), balance improved for most covariates, but some residual imbalance remained and overlap was limited. In the main weighted analyses, there were no statistically significant age-group differences in OS (HR 0.832, 95% CI 0.554–1.248; p = 0.372) and PFS (HR 0.794, 95% CI 0.577–1.093; p = 0.156); supportive results were also not statistically significant. These exploratory observations do not establish equivalence or an age-specific treatment effect, and interpretations should consider the retrospective design, complete-case weighting, limited overlap, and residual confounding. These findings provide descriptive long-term outcomes for older patients receiving avelumab maintenance in Japanese practice.
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,690
Funder: Merck KGaA
OpenAlex ID: W7237258644
FWCI:
Cites: 13
Cited by:
Related to: 10